{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27
  ],
  "modelUsed": "gpt-5.2",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ALXN1840 Repeat-Dose Treatment (15 mg/day with titration to 30 mg/day)",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Single-arm, open-label repeat-dose study in participants with Wilson disease. Participants initiate ALXN1840 15 mg/day on Day 1 for approximately 28 days, followed by titration to 30 mg/day on Day 29 after Safety Review Committee review of available safety data through Day 23. Adaptive feature allows remaining on 15 mg/day for the duration if safety concerns; dose range allowed 15 mg every other day to 30 mg/day.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '15 mg/day', 'startDay': 1, 'endDay': 28, 'description': 'Initial treatment period at 15 mg/day (minimum ~4 weeks).'}, {'dose': '30 mg/day', 'startDay': 29, 'endDay': 39, 'description': 'Titrated dose period planned from Day 29 through end of main collection period (Day 39); may remain at 15 mg/day if safety concerns.'}]"
          }
        ]
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_1",
        "epochId": "epoch_6",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_1",
        "epochId": "epoch_7",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_1",
        "epochId": "epoch_8",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_1",
        "epochId": "epoch_9",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_1",
        "epochId": "epoch_10",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Cohort 1 (Treatment experienced)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received Wilson disease therapy for > 28 days (includes standard of care therapies or ALXN1840)."
      },
      {
        "id": "cohort_2",
        "name": "Cohort 2 (Treatment naïve)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received Wilson disease therapy for ≤ 28 days."
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 10,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "controlType": {
        "code": "No Treatment",
        "codeSystem": "USDM",
        "decode": "No Treatment"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Hepatology",
        "Rare Disease"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": "No Treatment",
      "therapeuticAreas": [
        "Hepatology",
        "Rare Disease"
      ]
    },
    "arms": [
      {
        "name": "ALXN1840 Repeat-Dose Treatment (15 mg/day with titration to 30 mg/day)",
        "type": "Experimental Arm",
        "description": "Single-arm, open-label repeat-dose study in participants with Wilson disease. Participants initiate ALXN1840 15 mg/day on Day 1 for approximately 28 days, followed by titration to 30 mg/day on Day 29 after Safety Review Committee review of available safety data through Day 23. Adaptive feature allows remaining on 15 mg/day for the duration if safety concerns; dose range allowed 15 mg every other day to 30 mg/day.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "15 mg/day",
            "startDay": 1,
            "endDay": 28,
            "description": "Initial treatment period at 15 mg/day (minimum ~4 weeks)."
          },
          {
            "dose": "30 mg/day",
            "startDay": 29,
            "endDay": 39,
            "description": "Titrated dose period planned from Day 29 through end of main collection period (Day 39); may remain at 15 mg/day if safety concerns."
          }
        ]
      }
    ],
    "cohorts": [
      {
        "name": "Cohort 1 (Treatment experienced)",
        "characteristic": "Patients who have received Wilson disease therapy for > 28 days (includes standard of care therapies or ALXN1840)."
      },
      {
        "name": "Cohort 2 (Treatment naïve)",
        "characteristic": "Patients who have received Wilson disease therapy for ≤ 28 days."
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Screening prior to enrollment/check-in; participants enrolled/registered on Day -7."
      },
      {
        "name": "Run-in Period (Diet equilibration)",
        "description": "Day -7 through Day -5; supports diet equilibration in the clinical research unit."
      },
      {
        "name": "Pretreatment Baseline Balance Collection",
        "description": "Day -4 through Day -1; pretreatment copper and molybdenum balance assessment. Copper chelators discontinued starting Day -4 if applicable."
      },
      {
        "name": "Inpatient Period 1",
        "description": "Day -8 to Day 9 in the clinical research unit; includes baseline and initial 15 mg/day collection during accumulation."
      },
      {
        "name": "Treatment Period 1 (15 mg/day)",
        "description": "Day 1 through Day 28 (approximately 28 days). Includes intake/output collection Day 1 through Day 8 (initial 15 mg/day collection) and steady-state assessments around Days 25-28."
      },
      {
        "name": "Outpatient Period",
        "description": "Typically Day 9 to Day 23 (may be extended up to an additional 14 days with Investigator approval); participants may be discharged Day 9 and return Day 22 or Day 23 (predose)."
      },
      {
        "name": "Inpatient Period 2",
        "description": "Day 23 to Day 40 in the clinical research unit; includes 15 mg/day steady state and 30 mg/day accumulation/steady state assessments."
      },
      {
        "name": "Treatment Period 2 (Titrated dose: 30 mg/day planned)",
        "description": "Begins Day 29 after SRC review; includes collection period Day 25 through Day 39 supporting both 15 mg/day steady state and 30 mg/day accumulation/steady state."
      },
      {
        "name": "End of Study (EOS) / Early Termination (ET)",
        "description": "Protocol defines EOS/ET visit; timing not specified in provided excerpt."
      },
      {
        "name": "Unscheduled (UNS)",
        "description": "Unscheduled visits/assessments may occur as needed."
      }
    ]
  }
}